Published on 16 May 2024 on GuruFocus.com via Yahoo Finance
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing. This transaction increased the insider's total holdings in the company to 67,700 shares.
Warning! GuruFocus has detected 5 Warning Signs with EDIT.
Editas Medicine Inc (NASDAQ:EDIT) is a biotechnology company focused on developing transformative gene editing therapies to treat a broad range of diseases.